Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 2,201Psychedelics and Drug StudiesReligion, Spirituality, and PsychologyCancer survivorship and care

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Open access

Abstract

Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose (1 or 3 mg/70 kg) vs. a high dose (22 or 30 mg/70 kg) of psilocybin administered in counterbalanced sequence with 5 weeks between sessions and a 6-month follow-up. Instructions to participants and staff minimized expectancy effects. Participants, staff, and community observers rated participant moods, attitudes, and behaviors throughout the study. High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. Participants attributed improvements in attitudes about life/self, mood, relationships, and spirituality to the high-dose experience, with >80% endorsing moderately or greater increased well-being/life satisfaction. Community observer ratings showed corresponding changes. Mystical-type psilocybin experience on session day mediated the effect of psilocybin dose on therapeutic outcomes. Trial Registration ClinicalTrials.gov identifier: NCT00465595

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0269881116675513

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Flow diagram showing participation across the study.
Figure 1. Flow diagram showing participation across the study.CC BY · PubMed Central
Figure 2. Within-session time-course of psilocybin effects on cardiovascular and observer-rated measures. Cardiovascular (systolic and diastolic blood pressure, and heart rate) and observer (i.e. monitor)-rated overall drug effect, visual effects with eyes closed (as described by the participant), and joy/intense happiness. Data points show means; brackets indicate 1 SEM; circles show data after the low dose (n = 50); squares show data after the high dose (n = 50). Filled squares indicate the dose conditions were significantly different at the indicated time-point (p<0.05, planned comparisons). Y-axes for observer ratings show maximum possible scores.
Figure 2. Within-session time-course of psilocybin effects on cardiovascular and observer-rated measures. Cardiovascular (systolic and diastolic blood pressure, and heart rate) and observer (i.e. monitor)-rated overall drug effect, visual effects with eyes closed (as described by the participant), and joy/intense happiness. Data points show means; brackets indicate 1 SEM; circles show data after the low dose (n = 50); squares show data after the high dose (n = 50). Filled squares indicate the dose conditions were significantly different at the indicated time-point (p<0.05, planned comparisons). Y-axes for observer ratings show maximum possible scores.CC BY · PubMed Central
Figure 3. Effects of psilocybin on selected outcome measures that were assessed at Baseline, Post-session 1 (5 weeks after Session 1), Post-session 2 (5 weeks after Session 2), and 6-month follow-up. Data points show means; brackets indicate 1 SEM; circles represent the group that received a low dose on the 1st session and a high dose on the 2nd session (n = 25, 25, 24, and 22 at Baseline, Post-session 1, Post-session 2, and 6 months, respectively); squares represent the group that received a high dose on 1st session and a low dose on the 2nd session (n = 26, 26, 25, and 24 at Baseline, Post-session 1, Post-session 2, and 6 months, respectively). Star symbol indicates a significant difference between the two groups at the Post-session 1 time-point (p<0.05, planned comparison). Cross symbol indicates a significant difference between the Post-session 1 and Post-session 2 time-points in the Low-Dose-1st (High-Dose-2nd) Group (p<0.05, planned comparison).
Figure 3. Effects of psilocybin on selected outcome measures that were assessed at Baseline, Post-session 1 (5 weeks after Session 1), Post-session 2 (5 weeks after Session 2), and 6-month follow-up. Data points show means; brackets indicate 1 SEM; circles represent the group that received a low dose on the 1st session and a high dose on the 2nd session (n = 25, 25, 24, and 22 at Baseline, Post-session 1, Post-session 2, and 6 months, respectively); squares represent the group that received a high dose on 1st session and a low dose on the 2nd session (n = 26, 26, 25, and 24 at Baseline, Post-session 1, Post-session 2, and 6 months, respectively). Star symbol indicates a significant difference between the two groups at the Post-session 1 time-point (p<0.05, planned comparison). Cross symbol indicates a significant difference between the Post-session 1 and Post-session 2 time-points in the Low-Dose-1st (High-Dose-2nd) Group (p<0.05, planned comparison).CC BY · PubMed Central
Figure 4. Effects of psilocybin on clinically significant response rate and symptom remission rate as assessed with clinician-rated measures of depression and anxiety. Data are percentage of participants fulfilling criteria at Post-session 1 (5 weeks after Session 1) and at 6 months. Asterisks indicates that the low and high-dose groups were significantly different at 5 weeks (p>0.001); data at 6 months show these effects were sustained at follow-up. See Table 6 for other details.
Figure 4. Effects of psilocybin on clinically significant response rate and symptom remission rate as assessed with clinician-rated measures of depression and anxiety. Data are percentage of participants fulfilling criteria at Post-session 1 (5 weeks after Session 1) and at 6 months. Asterisks indicates that the low and high-dose groups were significantly different at 5 weeks (p>0.001); data at 6 months show these effects were sustained at follow-up. See Table 6 for other details.CC BY · PubMed Central
Figure 5. Relationship between the Mystical Experience Questionnaire (MEQ30) total score assessed at end of Session 1 and several illustrative outcome measures assessed 5 weeks after Session 1. Each panel shows scores on an outcome measure assessed 5 weeks after Session 1 as a function of the total MEQ30 score obtained 7 h after psilocybin administration on Session 1. MEQ30 scores are expressed as a percentage of maximum possible score. Data points represent individual participants (n = 50 or 51); blue circles represent the group that received the low dose on the 1st session; red squares represent the group that received the high dose on the 1st session. Correlation coefficients and p-values are shown.
Figure 5. Relationship between the Mystical Experience Questionnaire (MEQ30) total score assessed at end of Session 1 and several illustrative outcome measures assessed 5 weeks after Session 1. Each panel shows scores on an outcome measure assessed 5 weeks after Session 1 as a function of the total MEQ30 score obtained 7 h after psilocybin administration on Session 1. MEQ30 scores are expressed as a percentage of maximum possible score. Data points represent individual participants (n = 50 or 51); blue circles represent the group that received the low dose on the 1st session; red squares represent the group that received the high dose on the 1st session. Correlation coefficients and p-values are shown.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

52 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 9

  1. Beck AT, 1987, BDI Beck Depression Inventory Manual
  2. Benson PL, 1993, Res Soc Sci Stud Religion, 5, 1
  3. Carhart-Harris RL, 2014, Front Human Neurosci, 8, 1
  4. ISCDD, 2003, GRID-HAMD-17 Structured Interview Guide
  5. McIntosh DN, 1999, Measures of Religiosity, 503
  6. Metzner R, 1965, Psychedelic Rev, 5, 3
  7. Ostuzzi G, 2015, Cochrane Database Syst Rev, 6, CD011006
  8. Reker GT, 1992, The Life Attitude Profile-Revised (LAP-R)
  9. VandeCreek L, 1999, Measures of Religiosity, 442

Cited by

See all 2,201

Metadata

Authors
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A.
Affiliations
Johns Hopkins University (US)
Corresponding author
Griffiths, Roland R
Venue
Journal of Psychopharmacology
Published
2016-11-30
Volume
30
Issue
12
Pages
1181-1197
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2558412547
Cited by
2,201
References
53
Citations by year
2026: 278 · 2025: 325 · 2024: 335 · 2023: 315 · 2022: 310 · 2021: 229 · 2020: 187 · 2019: 73 · 2018: 77 · 2017: 54 · 2016: 14
FWCI
97.18
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute on Drug Abuse (R01DA003889)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Social Sciences › Health › Religion, Spirituality, and Psychology
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
psilocybin, depression, anxiety, cancer patients, psychedelic therapy, dose-response relationship, mystical experience, fear of death, quality of life, meaning of life, optimism, well-being, sustained treatment effects
MeSH terms
Anxiety, Attitude, Depression, Double-Blind Method, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Neoplasms, Psilocybin, Quality of Life, Surveys and Questionnaires, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. https://app.cochat.ai/papers/10.1177/0269881116675513
The paper
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116675513

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.